Skip to main content
. Author manuscript; available in PMC: 2024 Jan 3.
Published in final edited form as: Brain Res. 2021 Nov 10;1774:147721. doi: 10.1016/j.brainres.2021.147721

Fig. 3.

Fig. 3.

Intrathecal AM1710 reversal of allodynia requires CB2R actions A, B, Intrathecal pre-treatment with the CB2R selective antagonist AM630, but not the CB1R antagonist AM251, blocks the bilateral reversal of allodynia by AM1710 in TRPV1(−/−) mice. ****p < 0.0001, vs. time matched CCI Vehicle-injected control (Tukey’s test), and results are mean ± S.E.M, n = 3 mice/group.